Margaret Hamburg gets HELP C'tee backing

7 May 2009

The US Senate's Health, Education, Labor and Pensions Committee has confirmed Margaret Hamburg, President Barack Obama's nominee for FDA  Commissioner, as was generally expected. The hearing was moved forward  one week, according to the New York Times, because of the increase in  cases of H1N1 influenza in the USA. Ms Hamburg fielded questions about  the federal government's response to the disease.

The minority Republicans on the Committee might have been tempted to  delay matters, in retaliation for Democratic stalling against previous  nominees in the administration of George W Bush (Marketletters passim).  However, the NYT suggested that demoting to Deputy Commissioner the  acting Commissioner, Joshua Sharstein, a former staffer of  Representative Henry Waxman (Democrat, California), as well as  previously an employee of drug industry critic the Public Citizen, would  make more tactical sense. The CQ Today newsletter also reported that  Republicans were concerned about legislation that would give the FDA  authority to regulate tobacco products.

Ms Hamburg's nomination must be confirmed by the full Senate, which is  not expected to pose any difficulties if Democrats remain united. With  the defection of former Republican Arlen Spector (Pennsylvania) this  month, there is now a 60-40 majority, which makes partisan filibustering  impossible and also has consequences for the passage of  legislation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight